MedTrace Logo

Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex

NCT07756138 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-08-10

No results posted yet for this study

Summary

This pilot study will look at whether the topical Birch Triterpenes (Filsuvez) gel is safe and helpful for adults and children 6 months of age and older who have moderate to severe epidermolysis bullosa simplex (EBS). The study will examine whether the gel can reduce the number of blisters, help wounds heal faster, and improve comfort by reducing pain and itching and making daily activities easier.

Conditions

  • Epidermolysis Bullosa Simplex

Interventions

DRUG

Filsuvez

All the participants will apply Filsuvez about 3% BSA for 3 months.

Sponsors & Collaborators

Principal Investigators

  • Joyce Teng, MD, PhD, FAAD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2027-07-02
Completion
2028-06-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07756138 on ClinicalTrials.gov